

Ajay Major

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1082050/publications.pdf>

Version: 2024-02-01

43
papers

379
citations

933447

10
h-index

888059

17
g-index

48
all docs

48
docs citations

48
times ranked

517
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 89-91.	27.0	52
2	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
3	Documenting Social Media Engagement as Scholarship: A New Model for Assessing Academic Accomplishment for the Health Professions. <i>Journal of Medical Internet Research</i> , 2020, 22, e25070.	4.3	36
4	Persistence of Ad26.COV2.S vaccine-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. <i>American Journal of Hematology</i> , 2022, 97, 519-526.	4.1	26
5	Using big data in pediatric oncology: Current applications and future directions. <i>Seminars in Oncology</i> , 2020, 47, 56-64.	2.2	25
6	Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. <i>Leukemia and Lymphoma</i> , 2021, 62, 1765-1769.	1.3	25
7	Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. <i>Cancer</i> , 2020, 126, 189-201.	4.1	17
8	Refractory vaccine-induced immune thrombotic thrombocytopenia (<scp>VITT</scp>) managed with delayed therapeutic plasma exchange (<scp>TPE</scp>). <i>Journal of Clinical Apheresis</i> , 2022, 37, 117-121.	1.3	17
9	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. <i>Haematologica</i> , 2022, 107, 1608-1618.	3.5	16
10	Routine vaccinations as a precipitant of adrenal crisis in adrenal insufficiency. <i>Internal Medicine Journal</i> , 2018, 48, 360-361.	0.8	11
11	Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1234-1243.	1.3	11
12	Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1208-1219.	2.1	10
13	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. <i>Blood</i> , 2020, 136, 27-28.	1.4	9
14	Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. <i>JCO Oncology Practice</i> , 2022, 18, e586-e599.	2.9	9
15	Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Current Treatment Options in Oncology</i> , 2018, 19, 33.	3.0	8
16	Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW). <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	1.3	8
17	To Bully and Be Bullied: Harassment and Mistreatment in Medical Education. <i>AMA Journal of Ethics</i> , 2014, 16, 155-160.	0.7	6
18	Impact of COVID-19 on Hematology-Oncology Fellowship Programs: A Quantitative and Qualitative Survey Assessment of Fellowship Program Directors. <i>JCO Oncology Practice</i> , 2022, 18, e551-e563.	2.9	6

#	ARTICLE	IF	CITATIONS
19	Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 39-46.	0.4	5
20	Reflective Writing about Near-Peer Blogs: A Novel Method for Introducing the Medical Humanities in Premedical Education. <i>Journal of Medical Humanities</i> , 2021, 42, 535-569.	0.7	4
21	Removing Barriers: A Confidential Opt-Out Mental Health Pilot Program for Internal Medicine Interns. <i>Academic Medicine</i> , 2021, 96, 686-689.	1.6	4
22	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
23	Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. <i>EJHaem</i> , 0, , .	1.0	3
24	Providing Effective Mental Health Support for Oncology Health-Care Workers in the COVID-19 Era: Responding Quickly but Carefully. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab031.	2.9	2
25	A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2759-2759.	1.4	2
26	The Missing Factor(s): Disseminated Amyloidosis Causing Coagulopathy Refractory to Plasma Transfusion. <i>American Journal of Medicine</i> , 2022, , .	1.5	2
27	Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. <i>JCO Global Oncology</i> , 2022, 8, e2100266.	1.8	2
28	Not Just Skin Deep: Distant Metastases from Cutaneous Squamous Cell Carcinoma. <i>American Journal of Medicine</i> , 2017, 130, e327-e328.	1.5	1
29	Needle in a Haystack: A Missed Case of Wound Botulism. <i>American Journal of Medicine</i> , 2019, 132, e677-e678.	1.5	1
30	Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
31	DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 698-709.	0.3	1
32	Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1000-e1008.	0.4	1
33	Bourbon. <i>JAMA Oncology</i> , 2017, 3, 1309.	7.1	0
34	Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 1267-1268.	4.1	0
35	Bending Versus Transforming the Drug Cost Curve. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 304-310.	2.0	0
36	Developing a Novel Resilience Curriculum for Internal Medicine Interns Using a Survey-Based Needs Assessment. <i>Journal of General Internal Medicine</i> , 2021, 36, 1451-1453.	2.6	0

#	ARTICLE	IF	CITATIONS
37	Risk and types of secondary primary malignancies in DLBCL survivors changes over time based on stage at diagnosis.. Journal of Clinical Oncology, 2018, 36, e19540-e19540.	1.6	0
38	Baseline PET-CT functional parameters to identify low-grade versus grade 3A follicular lymphoma.. Journal of Clinical Oncology, 2018, 36, e19541-e19541.	1.6	0
39	Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma. Blood, 2019, 134, 4126-4126.	1.4	0
40	Utility Estimation of Rituximab Versus Bendamustine-Rituximab Induction in Indolent Non-Hodgkin Lymphomas Using Patient-Reported Quality of Life Survey Data. Blood, 2021, 138, 4013-4013.	1.4	0
41	Outcomes of Histological Variants of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): A Single-Center Retrospective Study. Blood, 2021, 138, 4548-4548.	1.4	0
42	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. Blood, 2020, 136, 24-26.	1.4	0
43	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. Blood, 2020, 136, 4-6.	1.4	0